DOD Tuberous Sclerosis Complex, Idea Development Award | W81XWH 21 TSCRP IDA

Opportunity Information: Apply for W81XWH 21 TSCRP IDA

The Department of Defense (DoD), through the U.S. Army Medical Research Acquisition Activity (USAMRAA), announced the Tuberous Sclerosis Complex (TSC) Research Program (TSCRP) Idea Development Award (IDA) under funding opportunity number W81XWH-21-TSCRP-IDA. This discretionary research funding opportunity supports science and technology and other research and development efforts aimed at generating high-impact advances in TSC research and, ultimately, improving outcomes and care for people living with TSC. The mechanism is offered as a grant or cooperative agreement, indicating that awards may be structured either as standard financial assistance or with a more active federal partnership depending on the project needs and the government role.

At its core, the Idea Development Award is designed for conceptually innovative projects that can open up new directions rather than simply extend existing work. The program is explicitly looking for ideas with the potential to yield high-impact findings and create new avenues of investigation in the TSC field. Proposals are expected to be grounded in a well-formulated, testable hypothesis and supported by a strong scientific rationale. While the award emphasizes innovation, it is not meant for purely speculative concepts without evidence; applicants need to show that the proposed work is ready to be tested in a rigorous, hypothesis-driven way.

Three key review priorities are emphasized: impact, innovation, and preliminary data. First, impact is central, and applicants are expected to explain both the short-term and long-term significance of the work. A competitive application should make a clear case for how successful results would meaningfully advance TSC biology, diagnosis, treatment approaches, or patient care practices, rather than producing narrow or incremental insights. Second, innovation is required and is defined in practical terms: the project should introduce or support a new paradigm, challenge existing assumptions, or approach an established problem from a fresh perspective. The program explicitly notes that “the next logical step” or incremental advances do not meet the innovation bar, and it leaves room for high-risk, high-reward approaches as long as they are conceptually strong and appropriately justified. Third, preliminary data are expected. The opportunity anticipates unpublished findings from the principal investigator’s lab or named collaborators and/or relevant evidence drawn from the published literature. In other words, the application should demonstrate feasibility and grounding in evidence, even if the main thrust of the proposal is bold and novel.

In terms of eligibility and administrative details, the opportunity lists eligibility as unrestricted, meaning it is open to any type of applicant organization unless additional eligibility constraints are stated elsewhere in the full announcement. The Catalog of Federal Domestic Assistance (CFDA) listing is 12.420. The posting date is April 1, 2021, with an original closing date of July 8, 2021. The opportunity anticipated making about four awards, and the listing shows an award ceiling of 0, which typically signals that the maximum award amount is not specified in the summary and would need to be confirmed in the full funding announcement or associated program guidance.

Overall, this DoD TSCRP Idea Development Award targets well-supported, hypothesis-driven projects that are genuinely creative and positioned to shift the field, with a strong emphasis on articulating how the work could translate into substantial progress for TSC research and patient care over both near-term and longer horizons.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Tuberous Sclerosis Complex, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 01, 2021.
• Applicants must submit their applications by Jul 08, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 TSCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: